Ingrezza for Tardive Dyskinesia Reviews - Drugs.com
Jan 11, 2020 · Reviews and ratings for Ingrezza when used in the treatment of tardive dyskinesia. 18 reviews submitted with a 5.5 average score.
Ingrezza (valbenazine) Reviews & Ratings by Patients – WebMD
I have an extreme form of Tardive Dystonia (full body, occasionally resulting in complete disability) with Functional Movement Disorder. Initially I was diagnosed with garden-variety Tardive …
- Reviews: 12
New Review on VMAT2 Inhibitors and Ingrezza for Treatment of Tardive …
Nov 20, 2025 · The review emphasizes the importance of understanding each VMAT2 inhibitor's mechanism, safety profile, and dosing for optimal treatment decisions in tardive dyskinesia. …
INGREZZA real-world patient cases in tardive dyskinesia
INGREZZA real-world patient cases in tardive dyskinesia See results with INGREZZA from real-world patients Review tardive dyskinesia (TD) movements across a broad range of adult …
Neurocrine Biosciences Presents Patient-Reported Outcomes
Jun 2, 2025 · KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, …
Valbenazine for the Treatment of Adults with Tardive Dyskinesia
This a comprehensive review of the literature regarding the use of Valbenazine in treating tardive dyskinesia. A primarily oral movement disorder induced by chronic exposure to certain classes …
Patient Stories | INGREZZA® (valbenazine) capsules
See stories of people with tardive dyskinesia (TD) and how treatment with INGREZZA® helped. See PI, including Boxed Warning, and Med Guide.
Neurocrine Biosciences Reports Patient-Reported Outcome Data …
Feb 27, 2025 · The KINECT-PRO™ Phase 4, open-label study was designed to evaluate patient reported outcomes on the use of INGREZZA ® (valbenazine) capsules in a tardive dyskinesia …
Ingrezza Treatment Associated with Sustained Improvements in Patients …
May 24, 2024 · Results of a post hoc analysis of the KINECT-4 study showed that the majority of participants with tardive dyskinesia (TD) who completed 48 weeks of once-daily Ingrezza …
Tardive Dyskinesia: Phase 3 Study Results Indicate ... - Patient …
Jun 21, 2024 · The Chief Medical Officer at Neurocrine Biosciences, Dr. Eiry Roberts, explained to PRNewswire that tardive dyskinesia is considered a debilitating condition which requires …